Company Overview and News

to your dashboard

Headline News

The List of Failed Alzheimer’s Drug Treatments Keeps Growing

2017-09-26 247wallst
If there is one cure or one treatment that could be the proverbial Holy Grail for a pharmaceutical or biotech company, it would be in a successful treatment of Alzheimer’s disease. This disease has ravaged an aging American population. More than 5 million Americans were already living with Alzheimer’s in 2014, and that number is expected to triple as the population continues to age. (372-2)

Global Electric Vehicles Forecasts, Analysis and Opportunities Report 2017-2037

2017-08-15 prnewswire
The "Electric Vehicles 2017-2037: Forecasts, Analysis and Opportunities" report has been added to Research and Markets' offering.

Global Huntington's Disease Therapeutics Market Growth at CAGR of 14.75%, 2017-2021 - Key Vendors are F. Hoffmann-La Roche, H. Lundbeck, Prana Biotechnology & Teva Pharmaceutical

2017-08-15 prnewswire
The "Global Huntington's Disease Therapeutics Market 2017-2021" report has been added to Research and Markets' offering.

Prana Biotechnology joins with Takeda to investigate lead drug

Prana Biotechnology Limited (ASX:PBT, NASDAQ:PRAN) has executed a research collaboration with Takeda Pharmaceuticals International to study Prana’s lead movement disorders compound.

Prana Biotechnology shares surge after journal publication

Shares in Prana Biotechnology (NADSAQ:PRAN) surged 19% and was earlier higher in New York as it said an article about early data on PBT434 had been accepted in a peer review journal.

Prana Bio shows some life; shares up 44%

2017-01-06 seekingalpha
Thinly traded Prana Biotechnology (PRAN +44%) continues its up move on an impressive 29x surge in volume. Shares have rallied almost 70% since trading resumed Tuesday.

Prana Biotech not quite there for start of European late-stage study of lead product candidate in Huntington's

2016-12-23 seekingalpha
With the aim of getting sign-off from regulators to initiate a Phase 3 clinical trial assessing lead product candidate PBT2 in Huntington's disease (HD), Prana Biotechnology (NASDAQ:PRAN) recently concluded meetings with the Medical and Healthcare Regulatory Agency in London and Medical Products Agency in Stockholm. Both recommended additional preclinical testing to establish the reversibility of the neurotoxicity observed in a dog study before considering a late-stage study in humans.

New Data From Trial Presented At American Neurological Association Annual Meeting

2016-10-18 devicespace
MELBOURNE, Australia--(BUSINESS WIRE)--Prana Biotechnology Ltd (ASX:PBT/NASDAQ:PRAN) is pleased to announce that further analysis of the cognitive results of its Reach2HD trial to treat Huntington Disease was presented in a poster1 at the American Neurological Association (ANA) Annual Meeting in Baltimore, United States.

WAVE Life Sciences IPO: Hold Off

2016-09-18 seekingalpha
WVE is pre-clinical; advanced programs are being studied to address Duchenne muscular dystrophy, Huntington’s disease, and inflammatory bowel disease (IBD).

New data from Prana's mid-stage study of lead product candidate in Huntington's disease showed improvements in thinking; shares up 11%

2016-09-18 seekingalpha
Thinly traded nano cap Prana Biotechnology (PRAN +11.3%) heads north on almost a 10x surge in volume, albeit on turnover of only 335K shares, in response to its announcement of new data from its completed Phase 2 clinical trial, REACH2HD, evaluating lead product candidate PBT2 in patients with Huntington's disease. The results were presented at the 20th Annual International Movement Disorder Society Congress in Berlin, Germany.

Parkinson's Disease Pipeline Report Covering 179 Companies

2016-08-01 prnewswire adds "Parkinson's Disease - Pipeline Review, H1 2016" market research report that provides an overview of the Parkinson's Disease's therapeutic pipeline with comprehensive information on the therapeutic development complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

Buy vTv Therapeutics For Its Novel Alzheimer's And Anti-Diabetic Drug Candidates.

2016-07-19 seekingalpha
VTv Therapeutics is an emerging company developing novel therapies in treatment of cognitive impairment in Alzheimer's disease and type 2 diabetes using proprietary TTP transitional technology.

Huntington’s Disease Market to reach $2.6 Billion by 2024: GlobalData

2016-05-13 financialexpress
The Huntington’s disease pipeline will see exciting new developments over the next decade as disease-modifying drugs transform the market landscape,’ says analyst The Huntington’s disease market will rise from around $252.6 million in 2014 to over $2.6 billion in 2024, representing a huge Compound Annual Growth Rate (CAGR) of 25.6 per cent, according to research and consulting firm GlobalData.

Appendix 4C - quarterly


ADR Ratio Change


Form 6-K


Prana Biotechnology Form 6-K (Current Report of Foreign Issuer)

  SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549    FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of January 2016   Prana Biotechnology Limited (Name of Registrant)   Level 2, 369 Royal Parade Parkville  Victoria  3052 Australia (Address of Principal Executive Office)   Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Appendix 4C - quarterly


AGM Presentation


Results of Meeting